Abstract
Lung cancer is characterized by high malignancy and the majority of patients are diagnosed at the advanced or late stage. Chemoradiotherapy has insufficient effect on this malignant tumor. At present the immune therapy has become a new choice for lung cancer treatment. Ipilimumab, antibody to programmed death-1, immune cells, cytokines, melanoma-associated antigen A3 vaccine, liposomal BLP25, belagenpumatucel-L and polypeptide vaccine have been proved effective for lung cancer through various clinical trials. Futhermore, most of them have been moved forward to phase Ⅲ clinical trials in order to get more strong evidence to support the immunotherapy incorporated into the multidisciplinary treatment of lung cancer. Key words: Lung neoplasms; Immunity, passive; Antibody, monoclonal
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
